bioAffinity Technologies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, bioAffinity Technologies sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
bioAffinity Technologies: 4 sponsored US clinical trials, 2 recruiting.
bioAffinity Technologies sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Lung Cancer (Diagnosis), with 1 trials.
Upper-quartile sponsor footprint
bioAffinity Technologies sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
NCT07168993
Collection of Sputum and Labeling for Lung Cancer
NCT03457415
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer
NCT03837600
Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
NCT02388074
Therapeutic Areas
What is open in the bioAffinity Technologies pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lung Cancer (Diagnosis) (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
bioAffinity Technologies: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
bioAffinity Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this bioAffinity Technologies page
4 registered trials is a research-attention snapshot, not an endorsement of bioAffinity Technologies or any single study.
- 2 of bioAffinity Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer (Diagnosis) is the condition bioAffinity Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer (Diagnosis) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. bioAffinity Technologies pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.